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Abstract 
We have recently shown that Natural Killer (NK) cells control survival and differentiation of 
Cancer Stem-like Cells (CSCs) through two distinct phenotypes of cytotoxic and anergic NK cells, 
respectively. In this report, brain CSCs and their serum and NK cell differentiated counterparts 
were studied. Serum-differentiated brain CSCs were significantly less susceptible to NK cells and 
CTL direct cytotoxicity as well as NK cell mediated Antibody Dependent Cellular Cytotoxicity 
(ADCC), whereas their CSCs were highly susceptible. The levels of CD44 and EGFR were higher 
in brain tumor CSCs when compared to the serum-differentiated tumors. No differences could be 
observed for the expression of MHC class I between brain tumor stem cells and their se-
rum-differentiated counterparts. Moreover, supernatants from the combination of IL-2 and an-
ti-CD16mAb treated NK cells (anergized NK cells) induced resistance of brain tumor CSCs to NK 
cell mediated cytotoxicity. Unlike serum-differentiated CSCs, NK supernatant induced differen-
tiation and resistance to cytotoxicity in brain CSCs correlated with the increased expression of 
CD54 and MHC class I. The addition of anti-MHC class I antibody moderately inhibited NK me-
diated cytotoxicity against untreated or serum-differentiated CSCs, whereas it increased cyto-
toxicity against NK supernatant differentiated tumors. Therefore, two distinct mechanisms govern 
serum and NK supernatant mediated differentiation of brain tumors. 
Key words: IFN-γ, NK, GBMs, brain stem cells 
Introduction 
Glioblastomas (GBMs) are among the tumors 
with poor prognosis. The current chemo- and ra-
dio-therapeutic strategies against GBMs have had 
limited success in either controlling the disease or 
establishing long lasting regression of these tumors in 
the patients, therefore, there is a clear need for effec-
tive therapies to control these tumors. There is also 
evidence that the differentiation status of tumor cells 
might affect their therapeutic outcome [1]. GBMs 
contain self-renewing, stem-like subpopulation with 
the ability to sustain tumor growth. These cells, also 
known as Cancer Stem-like Cells (CSC), share certain 
phenotypic characteristics with untransformed stem 
cells and are resistant to chemo- and radio-therapy 
due to increased expression of multi-drug resistance 
and DNA mismatch repair genes. In recent years, T 
cell based immune-therapies have gained some pop-
ularity and were shown to have some success in 
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treatment of certain patients, however, because of a 
lower MHC class I expression on GBMs the effec-
tiveness of CTL based therapies may be limited. On 
the other hand, NK cells should be able to target such 
tumors since they are known to kill tumors with no or 
decreased levels of MHC class I expression. Indeed, it 
is shown that NK cells are recruited to the brain and 
CNS during pathological diseases such as Multiple 
Sclerosis and during non-pathological human brain 
and have a significant role in immune regulation [2]. 
In GBMs NK cells are found in the tumor microenvi-
ronment and are shown to be suppressed by the tu-
mor and the effectors of the immune system [2]. In 
addition, targeting GBMs with the NK cells increases 
the survival of the animals [3]. Therefore, it is clear 
from the previous studies that NK cells based im-
munotherapies may have beneficial effect in patients. 
Immunosuppression and tumor escape from 
immune recognition are thought to be major factors 
responsible for the establishment and progression of 
cancer, however, neither underlying physiological 
relevance nor the exact mechanisms by which im-
munosuppression occurs are well understood. It is 
shown that freshly isolated tumor infiltrating NK cells 
are not cytotoxic to autologous tumors. Moreover, NK 
cells obtained from the peripheral blood of patients 
with cancer have significantly reduced cytotoxic ac-
tivity [4-7]. In addition, NK cell cytotoxicity is sup-
pressed after their interaction with stem cells [8-10]. In 
contrast, interaction of NK cells with the resistant 
tumors did not result in suppression of NK cell cyto-
toxicity [11, 12]. 
Increased NK cell cytotoxicity and augmented 
secretion of IFN-γ were observed against Oral Squa-
mous Cancer Stem Cells (OSCSCs) when compared to 
differentiated Oral Squamous Carcinoma Cells (OS-
CCs) [13]. More importantly, OSCSCs expressed 
CD44high CD326high CD26high CD166low CD338+ oral 
stem cell markers [1, 13]. We have also demonstrated 
that NK cells were able to lyse hMSCs, hDPSCs, 
hESCs and hiPSCs significantly more than their dif-
ferentiated counterparts [13]. In addition, 
de-differentiation by blocking NFκB in oral tumors 
was able to increase NK cell mediated cytotoxicity 
[13-15] and elevated CD44 surface receptor expression 
(data not shown).  
We have previously shown that K562, an NK 
sensitive tumor, causes loss of NK cell cytotoxicity 
while increasing IFN-γ secretion by the NK cells, a 
term which we coined as split anergy [11, 15-20]. On 
the other hand NK resistant tumors, such as RAJI 
cells, do not induce split anergy in NK cells [11, 18]. 
Significant down-modulation of CD16 receptor and 
decreased NK cell cytotoxic function were also seen in 
patients with cancer including those of the oral and 
ovarian cancer patients [21, 22].  
 In this paper we studied the function of NK cells 
against three GBM CSCs, their serum-differentiated 
and NK supernatant differentiated counterparts. 
Overall, our data indicates that there is heterogeneity 
within the subpopulations of GBM CSCs as seen by 
the levels of CSC surface marker expression and sus-
ceptibility to NK cell mediated cytotoxicity. In addi-
tion, NK cells are highly effective in eliminating CSCs 
in GBMs. However, differentiation and resistance of 
GBM tumors by the factors present in serum and 
those secreted by anergized NK cells may limit lysis of 
tumors by competent NK cells. Such decrease in lysis 
of differentiated GBM tumors by the NK cells com-
pounded by the known inactivation of NK cell cyto-
toxic function by the effectors of the tumor microen-
vironment may significantly curtail effectiveness of 
NK cells in controlling the progression of GBM tu-
mors.  
Materials and Methods 
Cell Lines, Reagents, and Antibodies 
RPMI 1640 supplemented with 10% FBS was 
used for the cultures of human NK cells. Stem-like 
GBMs were isolated from freshly resected human 
tumor tissues as described previously [23], and they 
were seeded at 1X105 cells/mL into culture flasks 
pre-coated with laminin (1mg/mL; BD Biosciences, 
CA) and Poly-L-Ornithine (15ug/mL; Sigma Aldrich, 
MO). The cells were cultured in DMEM/F12 medium 
(Gemini Bio-Products, CA) supplemented with peni-
cillin G, streptomycin sulfate, B-27 (1:50; Gemini 
Bio-Products, CA), recombinant human Fibroblast 
Growth Factor (hFGF-2, 20ng/mL, R&D Systems, 
MN), recombinant human Epidermal Growth Factor 
(hEGF, 20ng/mL, R&D Systems, MN) and Leukemia 
Inhibitory Factor (LIF, 1000U/mL). The medium was 
refreshed every 3 days. Recombinant IL-2 was ob-
tained from NIH-BRB. The human NK purification 
kits were obtained from Stem Cell Technologies 
(Vancouver, Canada). The antibodies for CD16 and 
CD44 were obtained from Biolegend (San Diego, CA). 
Anti-MHC class I were prepared in our laboratory 
and 1:100 dilution was found to be the optimal con-
centration to use. EGFR antibody (Erbitux) was pur-
chased from UCLA pharmacy. 
Transplantation of CSCs into the immunode-
ficient mice  
Tumor formation was performed as described 
previously [23]. 45-47 days later, all mice injected with 
two glioblastoma CSCs X01GB, X02GB and one ana-
plastic oligoastrocytoma X03AOA developed malig-
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nant brain tumors. Intracranial tumors generated by 
all three tumor lines demonstrated high infiltration 
into the surrounding cerebral cortex as evidenced by 
an unclear demarcation between the tumors and the 
normal tissues.  
Purification of NK cells  
 NK cells were purified from healthy donors us-
ing negative isolation kits from Stem Cell Technolo-
gies, Vancouver, Canada, as described previously 
[11]. Written informed consents approved by UCLA 
Institutional Review Board (IRB) were obtained from 
the blood donors and all the procedures were ap-
proved by the UCLA-IRB. 
Purification of T cells and the generation of 
CTLs 
X02GB cells were irradiated at 7,000 rads from a 
60Co source. PBMCs were cultured with X02GB cells 
for 14 days at a responder to stimulator ratio of 15:1 in 
RPMI-1640 containing 10% FBS and 60 IU IL-2/mL. 
Daily lactic acid concentrations were used to deter-
mine if replenishment with fresh culture medium was 
necessary. CD8+ T cells were purified negatively using 
T cell isolation kit (Stem Cell Technologies, Vancou-
ver, Canada).  
GBM CSCs differentiation with serum or NK 
cell supernatant  
To differentiate with serum, the brain CSCs were 
cultured in DMEM medium supplemented with 10% 
FBS for a period of 4 weeks. To differentiate with NK 
cell supernatants, NK cells were left untreated or 
treated with the combination of anti-CD16mAb 
(3ug/ml) and IL-2 (1000 units/ml) for 18- 24 hours 
before the supernatants were removed and used in 
differentiation experiments. The amounts of IFN-γ 
produced by activated NK cells were assessed with 
IFN-γ ELISA (Biolegend, CA). Serum-differentiated 
XO2GB (XO2GB-S) were further selected for differen-
tiation with the NK cell supernatants. Differentiation 
of XO2GB-S with NK cell supernatants was conducted 
with gradual daily addition of increasing amounts of 
NK cell supernatants. XO2GB-S required on average a 
total of 0.035pg of IFN-γ containing supernatants 
from IL-2+anti-CD16mAb treated NK cells per tumor 
cell during a 7 day treatment, whereas XO2GB CSCs 
required 0.070pg of IFN-γ containing supernatants 
from IL-2+anti-CD16mAbmAb treated NK cells per 
tumor cell for 7-10 days to promote differentiation 
and resistance to NK cell mediated cytotoxicity. Ini-
tially 1X106 tumor cells were cultured and treated 
with NK supernatants for differentiation. Afterwards, 
target cells were rinsed with 1X PBS, detached and 
used for experiments. 
Surface Staining   
Staining was performed by labeling the cells 
with antibodies as described previously [11, 17, 24].  
51Cr release cytotoxicity assay 
The 51Cr release assay was performed as de-
scribed previously [25] and the LU 30/106 was calcu-
lated by using the inverse of the number of effector 
cells needed to lyse 30% of target cells X100.  
Statistical analysis 
An unpaired, two-tailed student t-test was per-
formed for the statistical analysis. One way ANOVA 
with a Bonferroni post-test was used to compare the 
different groups. 
Results 
Characterization of brain tumor stem cells and 
their serum-differentiated counterparts 
X01GB and X02GB and X03AOA CSCs [23, 26, 
27] and their serum-differentiated counterparts 
(XO1GB-S, XO2GB-S and XO3AOA-S) were used to 
determine surface expression of key receptors. The 
brain CSCs exhibited a rounded morphology, which 
upon differentiation with serum demonstrated flat 
fibroblast-like spindle shape cells (Fig. 1A). CSCs 
formed tumors in the brain of immunodeficient mice 
with high proliferative capacity (Fig. 1B). The levels of 
CD44 were the highest in X01GB and X02GB and 
lower in X03AOA CSCs (Fig. 1C). Se-
rum-differentiation caused significant decreases of 
CD44 surface expression in all 3 CSCs; however, 
X03AOA exhibited the least decrease in CD44 expres-
sion after differentiation (Fig. 1C). EGF receptor ex-
pressions were significantly higher in all 3 brain CSCs 
when compared to their differentiated counterparts 
(Fig. 1C). X02GB had the highest EGF receptor ex-
pression, followed by X03AOA and the least expres-
sion was observed on X01GB. In contrast, no con-
sistent differences could be observed for the expres-
sion of MHC class I and the levels were not changed 
significantly after differentiation of CSCs (data not 
shown). The profiles of U87 GBM cell line were simi-
lar to those of the differentiated primary GBM tumors 
(Fig. 1C).  
X02GB CSCs were lysed significantly more 
than X01GB and X03AOA CSCs. 
Both untreated and IL-2 treated NK cells medi-
ated the highest lysis against X02GB, followed by 
X01GB and the least NK cell mediated lysis was ob-
served against X03AOA (Fig. 2A). Treatment of NK 
cells with anti-CD16mAb with and without IL-2 sig-
nificantly diminished NK cell cytotoxicity against all 
three brain tumor cells. Lysis of brain CSCs by NK 
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cells was significantly more when compared to U87 
GBM cell line (Fig. 2A).  
Differentiation of brain CSCs with serum de-
creased susceptibility to NK cell mediated 
cytotoxicity 
Differentiation of all three brain CSCs with se-
rum resulted in a significant decrease in NK cell me-
diated cytotoxicity (Fig. 2B). Decrease in NK cell me-
diated cytotoxicity was observed in untreated as well 
as IL-2 and IL-2+anti-CD16mAb treated NK cells 
when added to serum-differentiated brain tumor cells 
(Fig. 2B). The highest decrease in NK cell mediated 
cytotoxicity could be observed in the most sensitive 
stem cells X02GB after differentiation. XO3AOA had 
the lowest decrease in IL-2 mediated cytotoxicity 
when differentiated (Fig. 2B).  
Differentiation of stem cells with serum de-
creased expression of EGFR and NK cell 
ADCC against brain tumors 
The levels of ADCC were found to be different 
from direct cytotoxicity and it correlated with the 
levels of expression of EGFR on the surface of the 
brain stem cells (Figs. 1C and 2C). X02GB had the 
highest expression of EGFR (Fig. 1C) and therefore, 
NK cells mediated the highest levels of ADCC against 
these cells (Fig. 2C). X03AOA expressed the next 
highest EGFR expression therefore, unlike the direct 
cytotoxicity where NK cells mediated the least cyto-
toxicity they had the second highest ADCC when 
compared to the other 2 cell lines (Fig. 2C). The lowest 
ADCC was observed against X01GB which expressed 
the lowest surface expression of EGFR (Fig. 2C).  
Differentiation of brain CSCs by serum de-
creased direct cytotoxicity as well as NK cell mediated 
ADCC (Fig. 2C). Differentiation of the CSCs by serum 
decreased the levels of EGFR expression on brain 
tumor cells and resulted in a decreased NK cell me-
diated ADCC against X02GB and X03AOA tumors 
(Figs. 1C and 2C). Similar results were obtained when 
differentiated XO1GB were used with NK cells in the 
presence of EGFR antibody Cetuximab (data not 
shown).  
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Fig. 1. X01GB, X02GB and X03AOA stem cells expressed significantly higher surface expression of CD44 and EGFR when compared to their se-
rum-differentiated counterparts. X01GB, X02GB and X03AOA cells were cultured in either non-serum (NS) culture or differentiated in the presence of serum as described 
in the Materials and Methods section. As shown in the figure the brain stem cells exhibited more of a rounded morphology, which upon differentiation with serum demonstrated 
flat fibroblast-like spindle shape cells (A). X01GB, X02GB and X03AOA cells (2x105 cells) were injected orthotopically into the brain of immunodeficient nude mice as described 
in the Materials and Methods section and histological analysis was performed by H&E staining. Right panel in Fig. 1B demonstrated that these tumors have high proliferative 
capacity in vivo (B). X01GB, X02GB and X03AOA stem cells and their serum-differentiated counterparts were stained with either isotype control antibody or PE conjugated 
antibodies to CD44 mAb (left panel), EGF-R mAb (right panel) as described in the Materials and Methods section. The levels of CD44 and EGF receptor expression on each cell 
type were determined by flow cytometric analysis. The numbers on the upper right hand corner of each histogram are the mean channel fluorescent intensities. One of three 
representative experiments is shown in this figure.  
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Fig. 2. X02GB were lysed significantly more than X01GB and X03AOA CSCs, and serum-differentiation decreased their susceptibility to NK cell medi-
ated cytotoxicity and increased their resistance against NK cell mediated ADCC. Highly purified NK cells (1X106 cells/ml) were either left untreated or treated with 
IL-2 (1000u/ml), anti-CD16mAb (3µg/ml) or a combination of IL-2 (1000u/ml) and anti-CD16mAb (3µg/ml) for 12-24 hours and used in cytotoxicity assay against X01GB, X02GB, 
X03AOA stem cells and U87 GBMs (A) and along with their serum-differentiated counterparts (B). Purified NK cells were left untreated or treated with IL-2 (1000 units/ml) for 
12-24 hours and then added to 51Cr labeled X01GB, X02GB and X03AOA stem cells and their serum-differentiated counterparts treated with and without Cetuximab (10µg/ml) 
(C). NK cell cytotoxicities were determined using a standard 51Cr release assay and the lytic units 30/106 were determined using inverse number of effectors required to lyse 30% 
of the tumor cells X 100 in Figs A-C. Differences between untreated or IL-2 and/or anti-CD16mAb treated NK cell killing against all 4 cell lines were significant at a p value of 
<0.05 in Figs A-C. One of four representative experiments is shown in this figure. 
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T cells lysed brain tumor stem cells more than 
their serum-differentiated counterparts 
Cytotoxic T cells were generated against XO2GB 
and used in killing assay against both the stem cells 
and their differentiated counterparts. As shown in 
Fig. 3 CD8+ T cells purified from PBMCs 
pre-stimulated with irradiated XO2GB to generate 
CTLs killed XO2GB stem cells, but they were unable 
to lyse their differentiated counterparts. The addition 
of anti-MHC-Class I antibody significantly blocked 
CTL mediated lysis of XO2GB stem cells. CTLs were 
unable to lyse either NK cell sensitive K562 or NK cell 
resistant Raji or NK cell sensitive OSCSCs (Fig. 3). The 
levels of CTL mediated lysis of XO2GB stem cells 
were significantly less than that mediated by the NK 
cells obtained from the same donor (Supplementary 
Fig. S1A). The addition of anti-MHC class I antibody 
did not change the resistance of XO2GB-S cells against 
CTLs. In contrast to CTLs, NK cells purified from the 
same donor significantly lysed OSCSCs and K562s, 
but not Raji cells (Figs. S1A and S1B) and the addition 
of anti-MHC class I antibody inhibited NK cell medi-
ated lysis of OSCSCs similar to that seen when an-
ti-MHC class I antibody was added to the cultures of 
CTLs with XO2GB stem cells (Supplementary Fig. 
S1A).  
 
 
Fig. 3. CTLs mediated cytotoxicity against stem-like GBMs but not their 
serum-differentiated counterparts. X02GB were irradiated at 7,000 rads from a 
60Co source. PBMCs were cultured with X02GB for 14 days at a responder to 
stimulator ratio of 15:1 in RPMI-1640 containing 10% FBS and 60 IU IL-2/mL. Daily 
lactic acid concentrations were used to determine if replenishment with fresh culture 
medium was necessary. CD8+ T cells were purified negatively using T cell isolation kit 
and cultured with stem-like 51Cr labeled XO2GB and XO2GB-S at different E:T ratios 
and cytotoxicity were determined in a 4 hour 51Cr release assay. Anti-MHC class I 
antibody was added at a 1:100 dilution. NK sensitive OSCSCs and K562 and NK 
resistant Raji cells were used as controls. Supernatants were then harvested and 
radioactivity counted using a gamma counter. Lytic units 30/106 cells were deter-
mined using inverse number of effector cells required to lyse 30% of the target cells X 
100. 
 
Supernatants from IL-2+anti-CD16mAb 
treated NK cells induced resistance of 
XO2GB-S to NK cell mediated cytotoxicity  
We next determined differences between 
non-serum treated XO2GB, XO2GB-S, and XO2GB-S 
differentiated by supernatants from the 
IL-2+anti-CD16mAb treated NK cells in regards to 
resistance to NK cell mediated cytotoxicity. Treatment 
of XO2GB-S with IL-2+anti-CD16mAb treated NK cell 
supernatants decreased NK cell mediated cytotoxicity 
significantly by freshly isolated untreated, IL-2 treat-
ed or IL-2+anti-CD16mAb treated NK cells (P<0.05) 
(Fig. 4A). Resistance of XO2GB-S to NK cell mediated 
cytotoxicity could also be observed after their treat-
ment with supernatants from IL-2 treated NK cells, 
however, the levels of resistance were significantly 
less when compared to those induced by 
IL-2+anti-CD16mAb treated NK cell supernatants 
(data not shown). The following profile emerged from 
these studies. XO2GB in the absence of serum were 
the most sensitive to NK cell mediated cytotoxicity, 
followed by XO2GB-S and the most resistance could 
be observed when supernatants from 
IL-2+anti-CD16mAb treated NK cells were used to 
differentiate XO2GB-S (Fig. 4A).  
When non-serum treated XO2GBs were differ-
entiated with supernatants from IL-2+anti-CD16mAb 
treated NK cells 68% inhibition in the cytotoxicity 
could be observed when untreated NK cells were 
used to assess cytotoxicity. However, only 36% de-
crease could be seen with IL-2 treated NK cells, 
whereas with XO2GB-S 75% and 74% inhibition with 
untreated and IL-2 treated NK cells could be seen, 
respectively. These experiments indicated that su-
pernatants from IL-2+anti-CD16mAb treated NK cells 
were able to induce resistance to XO2GB-S more effi-
ciently than non-serum treated XO2GBs. 
 
Induction of NK resistance in XO2GB-S by 
supernatants from IL-2+anti-CD16mAb 
treated NK cells correlated with the increased 
expression of CD54 and MHC class I  
 We then assessed correlation between resistance 
to NK cells induced by the supernatants from 
IL-2+anti-CD16mAb treated NK cells in XO2GB-S 
with key cell surface receptor expression. Among 
many surface receptors tested CD54 and MHC class I 
expression were found to correlate significantly with 
the differentiation and resistance of NK 
sup-differentiated XO2GB-S (Fig. 4B). As shown in 
Fig. 4B, the levels of CD54 and MHC class I increased 
substantially on XO2GB-S in the presence of 
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IL-2+anti-CD16mAb treated NK cell supernatants. 
Supernatants from untreated NK cells did not have 
significant effect on surface expression of XO2GB-S 
(Fig. 4B). No significant differences could be seen for 
the expression of CD54 and MHC class I expression 
between XO2GB CSCs and XO2GB-S cells (Fig. 4B).  
 
 
Fig. 4. Increased resistance to NK cell mediated cytotoxicity and increased expression of CD54 and MHC class I on X02GB-S differentiated with super-
natants from IL-2+anti-CD16mAb treated NK cells. Highly purified NK cells were left untreated or treated with the combination of IL-2 (1000 units/ml) and an-
ti-CD16mAb (3 µg/ml) for 24 hours, after which the supernatants were removed and used for the treatment of X02GB-S cells for 7 days. X02GB-S in the absence of NK 
supernatants was used as controls. Similar amounts of supernatants from untreated NK cells and those cultured with IL-2+anti-CD16mAb treated NK cells were used to treat 
X02GB-S to induce differentiation. Afterwards, the cells were rinsed with 1X PBS, detached from the tissue culture plate and used in a standard 51Cr release assay against freshly 
isolated untreated NK, IL-2 (1000 units/ml) and the combination of IL-2 (1000 units/ml) and anti-CD16mAb (3µg/ml) treated NK cells (A). X02GB-S was differentiated with NK 
supernatants as described in figure 4A and the surface expression of CD54 and MHC class I on untreated X02GB, untreated X02GB-S and NK supernatant treated X02GB-S 
were assessed after 7 days of differentiation using PE conjugated antibodies followed by flow cytometric analysis. Isotype control antibodies were used as controls. The numbers 
on the right hand corner are the percentages and the mean channel fluorescence intensities in each histogram (B).  
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Fig. 5. Antibody to MHC-class I inhibited NK cell mediated cytotoxicity 
moderately against stem-like XO2GB and XO2GB-S whereas it increased 
substantially against IL-2+anti-CD16mAb NK supernatant differentiated 
XO2GB-S. NK cells (1X106/ml) were treated with IL-2 (1000 units/ml) 12-24 hours 
before they were cultured with 51Cr labeled XO2GB (A), XO2GB-S (B) or NK 
supernatant differentiated X02GB-S cells (C) at different E:T ratios in the presence 
and absence of anti-MHC-Class I mAb (1:100 dilution). X02GB-S differentiation by 
NK supernatant was performed as described in figured 4A. Percent cytotoxicity was 
obtained at different effector to target ratio, and the lytic units 30/106 cells were 
determined using inverse number of NK cells required to lyse 30% of the tumor cells 
X100. 
 
MHC class I antibody augmented NK cell cy-
totoxicity against IL-2+anti-CD16mAb treated 
NK supernatant differentiated XO2GB-S 
whereas it inhibited cytotoxicity against 
XO2GB CSCs  
As shown in Fig. 5, the addition of anti-MHC 
class I mAb to the cultures of NK cells with stem like 
XO2GB (Fig 5A) or XO2GB-S (Fig. 5B) decreased NK 
cell cytotoxicity by 36.5% and 16.4%, respectively, 
whereas it increased NK cell cytotoxicity (56.9%) 
against XO2GB-S differentiated with the supernatants 
from IL-2+anti-CD16mAb treated NK cells (Fig. 5C). 
Increase in NK cell cytotoxicity in the presence of 
MHC class I antibody in IL-2+anti-CD16mAb super-
natant differentiated XO2GB-S correlated with the 
increased expression of MHC class I on XO2GB-S (Fig. 
4B). Both XO2GB and XO2GB-S in the absence of su-
pernatants from IL-2+anti-CD16mAb treated NK cells 
exhibited no or lower expression of MHC class I (Fig. 
4B). Similarly, anti-MHC class I mAb decreased NK 
cell mediated cytotoxicity when added to the cultures 
of NK cells with OSCSCs, whereas it increased when 
added to IL-2+anti-CD16mAb treated NK superna-
tant differentiated OSCSCs (Supplementary Fig. S1A 
and [1]). The addition of antibodies to MHC class I 
increased NK cell cytotoxicity significantly when 
added to well- differentiated OSCCs isolated from 
oral cancer patient which exhibited higher surface 
expression of MHC class I [1]. 
Discussion 
In this report we present evidence that NK cells 
target brain cancer stem cells significantly more than 
their differentiated counterparts. The phenotypic 
characteristics and the nature of stemness of the three 
brain tumor stem cells used in our study has been 
established and reported previously [26]. Our results 
demonstrated that NK cells were able to lyse X02GB 
tumors significantly more than either X01GB or 
X03AOA brain tumor stem cells. The lysis of brain 
tumor stem cells were closely correlated with the ex-
pression of CD44 levels on the cells. Se-
rum-differentiation of brain stem cells decreased 
CD44 expression on all the lines, however, more 
dramatic decreases could be observed for X02GB and 
X01GB and less for X03AOA cells.  
 Dissociation between direct cytotoxicity and 
ADCC was found when NK cell cytotoxicity was 
measured against X01GB and X03AOA brain stem 
cells. Whereas NK cells mediated lower levels of di-
rect cytotoxicity against X03AOA when compared to 
X01GB, the levels of NK cell ADCC was higher 
against X03AOA brain stem cells as compared to 
X01GB in the presence of Cetuximab, and it correlated 
with the higher expression of EGFR on X03AOA. In-
terestingly, the levels of EGFRvIII gene expression 
was higher in X01GB and X03AOA stem cells and no 
expression could be seen in X02GB [26]. These results 
may indicate different levels of stemness in the three 
brain stem cells, and the ability of NK cells to be the 
predictor of the levels of stemness in the tumors. 
 Both NK and CTLs were able to lyse XO2GB 
stem cells significantly more than their differentiated 
counterpart, albeit the levels of NK cell cytotoxicity 
were much higher than those obtained by CTLs. In-
deed, peptide specific targeting of GBM stem-like 
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tumors but not their serum-differentiated counter-
parts by specific CTLs was shown previously [28]. As 
expected, the addition of anti-MHC-Class I antibody 
inhibited CTL mediated lysis of XO2GB, and moreo-
ver, CTLs were not able to lyse NK cell sensitive K562 
or OSCSCs.  
The magnitude of NK cell cytotoxicity in the 
presence of MHC class I mAb correlated with the lev-
els of MHC class I surface expression on tumors. In-
hibition of NK cell cytotoxic function by anti-MHC 
class I antibody was seen in the presence of GBM and 
OSCSC stem-like cells which expressed very low lev-
els of MHC class I, whereas increased cytotoxicity was 
seen when the cells were differentiated which ex-
pressed higher levels of MHC class I. Stem-like tu-
mors which were NK cells supernatant differentiated 
or were isolated from well differentiated tumors ex-
hibited increased NK cell mediated cytotoxicity in the 
presence of anti-MHC class I antibody correlating 
with the increased expression of surface MHC class I. 
Indeed, we have previously demonstrated that an-
ti-MHC class I antibody when added in the absence of 
CD16 receptor triggering on NK cells had no inhibi-
tory activity on cytotoxic function of NK cells, how-
ever, it mediated significant inhibition of NK cell cy-
totoxicity when added in the presence of CD16 re-
ceptor triggering [19]. Based on these observations we 
speculated that since XO2GB and OSCSCs mediate 
significant receptor mediated activation of NK cells, 
the addition of anti-MHC class I antibody may serve 
to inhibit NK cell mediated cytotoxicity as seen in 
Figs. 5A and S1A. However, when stem cells are dif-
ferentiated, since NK cells are not activated or acti-
vated moderately, they are not inhibited by the addi-
tion of anti-MHC class I antibody, therefore, they are 
able to mediate lysis of the high MHC expressing 
tumors in the presence of anti-MHC class I mAb. 
Thus, the lack of inhibition of NK cell cytotoxic func-
tion in addition to increased expression of MHC class 
I on the target cells are two factors which could con-
tribute to the observed increases in the lysis of the 
differentiated tumors in the presence of anti-MHC 
class I antibody. Lysis of differentiated tumors in the 
presence of anti-MHC antibodies could be due to ei-
ther blocking of inhibitory MHC class I signals which 
activates NK cells or it could be due to the 
cross-linking of MHC class I on the tumor cells which 
delivers a death signal to the tumors or both. These 
possibilities are under investigation in our laboratory 
and are the subject of a follow up study. The observa-
tions with the anti-MHC class I antibody have signif-
icant implications regarding the function of NK and 
CTLs. It indicates that these cells may have a common 
mode of action when they encounter stem cells or 
undifferentiated cells, however, their mode of action 
may differ when they encounter differentiated cells.  
In agreement with the results obtained in this 
report, we have previously demonstrated that the 
stage of maturation and differentiation of healthy 
untransformed stem cells as well as transformed tu-
morigenic cancer stem cells is predictive of their sen-
sitivity to NK cell lysis [13, 14, 29-33]. Our work col-
lectively suggests that anergized NK cells are as im-
portant as the non-anergized NK cells in their effector 
functions. NK cells are not only important for the 
removal and shaping of the size of the stem cells but 
also their differentiation. Indeed, we have previously 
coined the concept of split anergy in NK cells which is 
induced by sensitive tumor cells and after triggering 
of the CD16 receptor on NK cells [12, 34-37]. Induction 
of split anergy in NK cell effector function has signif-
icant physiological consequences since it can ulti-
mately aid in driving differentiation of a 
sub-population of surviving healthy as well as trans-
formed stem cells after initial selection by the NK 
cells. 
Much higher amounts of NK supernatants con-
taining IFN-γ were required to induce resistance to 
NK cell mediated cytotoxicity and growth arrest in 
XO2GB when compared to OSCSCs. Unlike OSCSCs, 
higher amounts of NK supernatants containing IFN-γ 
were unable to either promote detachment or induce 
substantial cell death in XO2GB. These experiments 
reveal crucial differences between tumor types in 
their responses to NK cell mediated differentiation, 
and may uncover the underlying mechanisms gov-
erning GBMs aggressive behavior and poor prognosis 
in patients.  
The inability of patient’s NK cells to contain 
GBM stem cells due to the proliferating cancer stem 
cells and conversion of NK cells to cytokine secreting 
cells may likely be one mechanism by which tumor 
cells may remain viable. Poorly differentiated tumors 
have unfavorable prognosis since the microenviron-
ment of these tumors are likely to condition a great 
majority if not all of the NK cells to support differen-
tiation of newly generated cancer stem cells, and as 
such these patients are likely to have more NK cells 
with no or low cytotoxic function. Therefore, these 
patients may benefit from repeated NK cell trans-
plantation for elimination of cancer stem cells. In this 
regard depletion of NK anergizing effectors such as 
monocytes via radiation or chemotherapeutic drugs 
before NK cell transplantation should in theory pro-
vide such strategy. However, this strategy may also 
halt or decrease the ability of NK cells to drive dif-
ferentiation of the tumors due to the removal of syn-
ergizing effect of monocytes with NK cells for secre-
tion of TNF-α and IFN-γ, leading to growth of cancer 
stem cells [13]. Alternatively, a strong tumor differen-
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tiating microenvironment may be induced by the 
synergistic effect of monocytes and NK cells. The 
benefit of such approach is the ability of chemother-
apeutic drugs to target differentiated tumors in addi-
tion to the lack of differentiated tumors to metasta-
size. Indeed, our recent in vivo data indicated that 
pancreatic cancer stem cells have the ability to grow 
faster and metastasize, whereas their differentiated 
tumors grew slower and remained localized for a long 
period of time without metastasizing (manuscript in 
prep).  
It is possible that the successful cancer therapy 
may lie between a balance in two abovementioned 
approaches. The most dangerous and devastating 
outcome of the cancer is its ability to deplete NK cells 
and other synergizing immune effectors. In this case, 
cancer stem cells will survive and remain poorly dif-
ferentiated, which are likely reasons for cancer inva-
sion and metastasis. NK cell immunotherapy in these 
patients should be highly beneficial in containing 
tumor progression and metastasis. 
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